GeneDx Holdings Corp. (WGS) Stock Analysis
Healthcare · Diagnostics & Research
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform... Read more
TrendMatrix rates GeneDx Holdings Corp. (WGS) as Sell with moderate confidence. The stock trades at $66.95 with +98.9% upside to the $133.17 price target. Overall score: 5.8/10 across 10 analysis dimensions. Reward/risk ratio: 30.9:1.
Passes 3/5 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates GeneDx Holdings Corp. (WGS) as Sell with moderate confidence. Score 5.8/10.
Take-profit target: $133.17 (+98.9% upside). Reward/risk ratio: 30.9:1. Stop-loss: $64.84.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Negative momentum; Elevated risk factors.
GeneDx Holdings Corp. trades at a P/E of N/A (forward 33.4). TrendMatrix value score: 7.3/10. Verdict: Sell.
13 analysts cover WGS with a consensus score of 4.2/5. Average price target: $157.
What does GeneDx Holdings Corp. do?GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric...
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.